A systematic review and meta-analysis of shRNA-IL-6-engineered CAR-T cells for B-cell Acute Lymphoblastic Leukemia: a stepping stone towards risk-free immunotherapy
{{output}}
Clinical application of chimeric antigen receptor (CAR)-T cells, especially those targeting CD19, stands as a breakthrough in treating relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Yet, preventing immune-related adverse events (IrAEs)... ...
